By Wendy Diller
Antibiotics—and especially hospital antibiotics--were made for biotech. Big Pharma often doesn't want to pursue them because their markets seem too...
Cubist ultimately wants its new hospital antibiotic Cubicin to replace the widely used vancomycin. To do that, it's got to demonstrate that Cubicin, recently approved for a single indication, is safe and effective for a broad spectrum of hard-to-treat infections. As the first company in four years to launch a new hospital antibiotic, Cubist may be a model for the handful of other small companies seeking to capitalize on the opportunity. These start-ups may be better suited than Big Pharma to address what experts see as an important but limited unmet medical need.
By Wendy Diller
Antibiotics—and especially hospital antibiotics--were made for biotech. Big Pharma often doesn't want to pursue them because their markets seem too...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.